Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 04/29/25
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyBusiness Wire • 04/28/25
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to DeclineZacks Investment Research • 04/24/25
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial ResultsBusiness Wire • 04/17/25
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare ConferenceBusiness Wire • 04/01/25
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025Business Wire • 03/29/25
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or BBusiness Wire • 03/28/25
siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 TrialsGlobeNewsWire • 03/28/25
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades StockBenzinga • 03/24/25
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?Zacks Investment Research • 03/24/25
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in CardiomyopathyZacks Investment Research • 03/21/25
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBioInvestors Business Daily • 03/21/25
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock JumpsBenzinga • 03/21/25
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Business Wire • 03/20/25
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?Zacks Investment Research • 03/14/25
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry LuminaryBusiness Wire • 03/05/25
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D DayBusiness Wire • 02/25/25